Navigation Links
Celtaxsys Restructures, Enhances Operational Focus
Date:9/9/2013

ATLANTA, Sept. 9, 2013 /PRNewswire/ -- Celtaxsys, Inc., an Atlanta-based pharmaceutical discovery and development company, announced today that it has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease.

As part of the restructuring, Dr. Michael Hanley has retired from his role as CEO and Chairman, and Dr. Brett Premack has stepped down as CTO.  Dr. H. Daniel Perez, a member of the Celtaxsys Board and former CEO of Berlex Biosciences and Presidio Pharmaceuticals, is serving as Chairman.

"We thank Dr. Hanley for his services as CEO and Chairman. Under his guidance, Celtaxsys has transformed into an exciting drug development company with a promising lead compound," said Dr. Perez.

In conjunction with these management changes, Celtaxsys is strengthening its clinical operations including bringing on Ed Philpot, MD, MBA, as CMO. Dr. Philpot has been serving as chair of the Medical Advisory Panel for the CTX-4430 development program for the past year and was formerly CMO at Smith & Nephew and prior to that Executive Director of Pulmonary Disease and Immuno-Inflammation at GSK, where he led several late stage clinical development programs. Celtaxsys has also expanded its internal Quality Assurance and Clinical Operations with additional key hires.

"We're excited to be able to bring more top talent into Celtaxsys," said Mike Masters, Celtaxsys Board Member. "As we continue to meet our clinical milestones, these changes demonstrate our strong support for the company and its programs".

About Cystic Fibrosis: Cystic Fibrosis is the most common life-shortening autosomal recessive disease among Caucasians, and lung disease is the leading cause of hospitalizations and death in adult CF patients. A hallmark of CF lung disease is excessive recruitment of blood polymorphonuclear neutrophils (PMNs) into the small airways (bronchioles) causing inflammation that results in elastic tissue destruction and progressive loss of lung function.

About CTX-4430: CTX-4430 is a once-daily oral drug candidate currently undergoing clinical trials for treatment of CF lung disease. It is a novel small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the key enzyme in production of the potent inflammatory mediator Leukotriene B4 (LTB4). LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in CF.

About Celtaxsys: Celtaxsys is a privately-held clinical stage drug discovery and development company focused on developing new treatments for inflammatory diseases by modulating innate immunity. The company is building a pipeline of first-in-class drugs with novel mechanisms of action. For more information, please visit www.celtaxsys.com.


'/>"/>
SOURCE Celtaxsys
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MDHI Enhances Service Offerings with New Options for Customers of Americas Largest Warehouse Club Chain - Announces New Extended Concierge Services
2. Marken Enhances Branch Operations
3. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
4. Virtua Enhances Efficiency with Integrated Identity and Access Management Solutions from Caradigm
5. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
6. Ekahau Enhances Real-Time Location System to Offer 20x More Scalability and Enhanced Reliability
7. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
8. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
9. SynteractHCR Enhances Adaptive Trial Capabilities
10. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
11. Pharmacists: Senate Bill Enhances Drug Supply Chain Security, but also Threatens Patient Access to Essential Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... Virginia (PRWEB) , ... September 21, 2017 , ... ... health in their communities, nine governmental public health departments have been awarded five-year ... accreditation decisions mean that the benefits of being served by a PHAB-accredited ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
Breaking Medicine News(10 mins):